Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible

Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible

Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and national registries is mixed, the search is ongoing....

Full description

Bibliographic Details
Main Authors:	Victor Serebruany, Moo Hyun Kim, Christian Thevathasan, Thomas Marciniak
Format:	Article
Language:	English
Published:	Georg Thieme Verlag KG 2018-01-01
Series:	TH Open
Subjects:	antiplatelet agents cancer safety registry faers
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1615253

Similar Items

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
by: E. Y. Kitaeva, et al.
Published: (2017-04-01)

Antiplatelet agents: an overview
by: Asma Haffouz, et al.
Published: (2023-01-01)

THE EFFECTS OF SHORT/LONG-TERM ADMINISTRATION OF DUAL ANTIPLATELET THERAPY ON RESTENOSIS IN PATIENTS WITH CAROTID ARTERY STENTING
by: İsmail Karluka, et al.
Published: (2022-12-01)

Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All‐Cause Mortality in Clinical Trials of Time‐Constrained Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention
by: John D. McClure, et al.
Published: (2020-08-01)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024-07-01)

Oral anticoagulants or antiplatelet drugs after heart valve reconstructive surgery: modern guidelines for the practitioners
by: V. P. Kuzmin, et al.
Published: (2024-04-01)

Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database
by: Jinhua Chen, et al.
Published: (2024-03-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

DENTAL MANAGEMENT AND BLEEDING COMPLICATIONS OF PATIENTS ON LONG-TERM ORAL ANTIPLATELET THERAPY. REVIEW OF EXISTING STUDIES AND GUIDELINES.
by: Atanaska Dinkova, et al.
Published: (2013-06-01)

Erratum: Evaluating cardiac disorders associated with triazole antifungal agents based on the US food and drug administration adverse event reporting system database
by: Frontiers Production Office
Published: (2024-05-01)

Risk of Gastrointestinal Bleed and Endoscopic Procedures on Antiplatelet and Antithrombotic Agents
by: Partha Pal, et al.
Published: (2019-01-01)

Safety of Perioperative Maintenance of Antiplatelet Agents in Elderly Patients Undergoing Lung Cancer Surgery
by: Hee Ju Hong, et al.
Published: (2024-07-01)

Effects of thienopyridine class antiplatelets on bleeding outcomes following robot-assisted radical prostatectomy
by: Masashi Kubota, et al.
Published: (2024-03-01)

Combined Antiplatelet Therapy Reduces the Proinflammatory Properties of Activated Platelets
by: Alexandra C.A. Heinzmann, et al.
Published: (2021-10-01)

Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
by: Jinfeng Zhu, et al.
Published: (2024-07-01)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024-08-01)

Risk Factors for Severe Bleeding Complications in Glaucoma Surgery and the Role of Antiplatelet or Anticoagulant Agents
by: Lauermann P, et al.
Published: (2022-04-01)

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications
by: Shinji Rho, et al.
Published: (2023-03-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE
by: S. Yu. Martsevich, et al.
Published: (2014-07-01)

ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE
by: S. Yu. Martsevich, et al.
Published: (2014-07-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024-09-01)

Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database
by: Xinyu Li, et al.
Published: (2024-10-01)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Jiahong Zhong, et al.
Published: (2024-10-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01)

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
by: Shichao Cui, et al.
Published: (2024-07-01)

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
by: Hao Lv, et al.
Published: (2022-08-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Factors Associated With Administration of Antiplatelet Therapy on The NIHSS Score in Acute Ischemic Stroke
by: Eddy Ratnaningsih Chrisstawati, et al.
Published: (2023-11-01)

Anticoagulant and antiplatelet therapy for chronic kidney disease patients
by: I. Dudar, et al.
Published: (2019-12-01)

Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
by: Dan Xu, et al.
Published: (2024-10-01)

Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention
by: Srivastava Padma
Published: (2010-01-01)

Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting
by: Deok Hee Lee, et al.
Published: (2012-02-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)